United-Imaging-Logo

Nuclear Medicine

ITM launches new oncology therapeutics division
By AuntMinnie.com staff writers
Lumara Bio will focus resources toward commercial readiness for ITM's lead drug candidate, lutetium-177 (Lu-177) edotreotide (ITM-11).
July 27, 2026
Lumara
Actineer completes Ra-226 recycling process to support Ac-225 supply
By AuntMinnie.com staff writers
This process aims to improve Ac-225 supply predictability and cost stability, as well as reduce waste generation.
July 14, 2026
Nuclear Medicine Worker Sm
Ratio Therapeutics signs Ac-225 supply agreement with PanTera
By AuntMinnie.com staff writers
Deal will support Ratio's alpha therapy programs.
June 30, 2026
Business Deal Corporate 400
Novel SST2-PET tracer shows promise in patients with NETs
By Will Morton
With a half-life of 3.3 hours, cyclotron-produced Cu-61 NODAGA-LM3 could allow delayed imaging and centralized distribution.
June 25, 2026
Maximum intensity projections showing biodistribution of Cu-61 NODAGA-LM3 (146 MBq) in a patient with a metastatic non-functional NET of the pancreas G2 (Ki-67: 5%) with lymph node, hepatic, osseous, and peritoneal as well as ovarian metastases. PET performed a 1-hour, 3-hours, and 18-hours post-injection show high and prolonged tumor uptake and excellent image contrast, with low uptake in the liver, intestinal tract, and other non-target organs.
Curium to invest €32M in French radiopharmaceutical facility
By AuntMinnieEurope.com staff writers
The investment will go toward development of a new production line for lutetium-177 PSMA-I&T, a targeted radioligand therapy.
June 1, 2026
France Flag Button 400
TAG1, NRG Pallas to advance Pb-212 supply for cancer therapies
By AuntMinnie.com staff writers
TAG1 and NRG Pallas aim to develop access to lead-212 (Pb-212) for cancer drug development across Europe.
April 22, 2026
A Rk Nx1 Fop15 Je H Jffj8rq D13
Astral Systems, Brazil's IPEN sign isotope production partnership
By AuntMinnieEurope.com staff writers
The partnership will initially focus on using Astral’s multistate fusion neutron generation technology to establish a new supply stream for actinium-225.
March 25, 2026
Nuclear Medicine Worker Sm
Video from ECR: 'The Stone Age didn’t end because of a lack of stones'
By Will Morton
In an interview at ECR, Dr. Andrei Iagaru, discussed the status of gamma-emitting imaging in theranostics and its future potential.
March 6, 2026
Andrei Iagaru
Global groups seek to expand access to theranostics
By AuntMinnieEurope.com staff writers
The International Centers for Precision Oncology Foundation and the World Federation of Nuclear Medicine and Biology are collaborating to expand access to theranostics.
February 27, 2026
Global Connections
Nuclear medicine group CEI joins Vidi imaging network
By AuntMinnieEurope.com staff writers
France's Vidi cooperative imaging network has welcomed its first nuclear medicine group, Centre d'Explorations Isotopiques (CEI).
February 23, 2026
France Flag Button 400
Unfilled vacancies and disparities persist in nuclear medicine
By Maryam Payne
Nuclear medicine specialists have high career satisfaction, but unfilled vacancies and career disparities persist, finds a workforce survey by the European Association of Nuclear Medicine (EANM).
February 19, 2026
Nuclear Medicine Worker Sm
PET develops key clinical role in neuroendocrine tumors
By Edna Astbury-Ward, PhD
Dual PET imaging and the NETPET score are proving increasingly useful in the prognosis and treatment of neuroendocrine tumors.
February 19, 2026
Dual PET imaging in Case Two illustrates a patient with discordant disease. FDG PET (b & d) shows FDG uptake in tail of pancreas primary lesion (yellow arrow), as well as multiple hepatic metastases (yellow boxes), with enlarged liver span. DOTATATE PET on left (a) shows several hepatic metastases that do not demonstrate DOTATATE uptake above background of liver parenchyma. The liver lesions in (c) demonstrate moderate FDG uptake in liver lesions, with no corresponding DOTATATE avidity (white box) or central photopenia (white arrow). This discordance in dual PET imaging corresponds to a NETPET score of 5. This suggests de-differentiated disease and a less favorable prognosis. The patient was not suitable for Lutate treatment and received chemotherapy.
Page 1 of 5
Next Page